New combo therapy shows promise for rare eye cancer
NCT ID NCT04552223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a combination of two drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. Twenty-seven participants received the treatment to see how many responded. The goal was to control the disease, not cure it, as ongoing management is typically needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer